Skip to main content
Top
Published in: Endocrine 2/2017

01-08-2017 | Original Article

Hypothalamo-pituitary-adrenal axis after a single epidural triamcinolone injection

Authors: Ali Iranmanesh, Dakshinamurty Gullapalli, Ravinder Singh, Johannes D. Veldhuis

Published in: Endocrine | Issue 2/2017

Login to get access

Abstract

Purpose

To quantify adrenocorticotropin and cortisol secretion after epidural glucocorticoid injection.

Methods

Eight men (ages 25–63 year) were studied at baseline, 1, 4, and 12 weeks after triamcinolone (80 mg) injection epidurally. Adrenocorticotropin (pg/mL) and cortisol (µg/dL) were measured every 10 min for 4 h, and after Corticotropin-releasing hormone (CRH) (1 µg/kg) injection.

Results

Epidural triamcinolone markedly suppressed: (1) pre-CRH injection ACTH (from 18 ± 3.1 to 4.8 ± 0.4: P < 0.01) and cortisol (from 12.2 ± 1.6 to 1.6 ± 0.3: P < 0.0001) at week 1, with recovery at 4 weeks, and (2) CRH-stimulated 3-h summed ACTH (from 633 ± 116 to 129 ± 10 pg/mL, P < 0.0001), and 3-h summed cortisol at week 1 (from 385 ± 29 to 56 ± 22 µg/dL, P < 0.0001) and 4 weeks (284 ± 53; P < 0.01). Serum cortisol was <18 µg/dL in eight of eight men at 4 weeks, and six of eight men at week 12. Urinary-free cortisol (µg/24 h) remained low at week 12: baseline (60 ± 6.5); week 1 (9.0 ± 1.3, P < 0.01); week 4 (36 ± 8.6) and week 12 (38 ± 4.1). Urinary cortisol/cortisone ratios rose at week 4 only. Serum triamcinolone peaked at week 1 (16/16 samples), declining at week 4 (13/16 samples) and week 12 (6/16 samples).

Limitations

Relatively small group.

Conclusion

Epidural triamcinolone suppresses unstimulated and CRH-stimulated ACTH and cortisol secretion for 1–4 weeks but urinary free cortisol ≥12 weeks. Suppression of ACTH and cortisol after glucocorticoid treatment is thus complex.
Literature
1.
go back to reference P.A.N. Chrousos, M.A. Magiakou, in Glucocorticoid Therapy and Adrenal Suppression, ed. by L. de Groote, G. Chrousos, K. Dungan, K.R. Feingold, A. Grossman, J.M. Hershman, C. Koch, M. Korbonits, R. McLachlan, M. New, J. Purnell, R. Rebar, F. Singer, A. Vinik (MDText.com, Inc., South Dartmouth, MA, 2000) (Online Textbook) P.A.N. Chrousos, M.A. Magiakou, in Glucocorticoid Therapy and Adrenal Suppression, ed. by L. de Groote, G. Chrousos, K. Dungan, K.R. Feingold, A. Grossman, J.M. Hershman, C. Koch, M. Korbonits, R. McLachlan, M. New, J. Purnell, R. Rebar, F. Singer, A. Vinik (MDText.com, Inc., South Dartmouth, MA, 2000) (Online Textbook)
2.
go back to reference C. Osterlund, R.L. Spencer, Corticosterone pretreatment suppresses stress-induced hypothalamic-pituitary-adrenal axis activity via multiple actions that vary with time, site of action, and de novo protein synthesis. J. Endocrinol. 208, 311–322 (2011)PubMedPubMedCentral C. Osterlund, R.L. Spencer, Corticosterone pretreatment suppresses stress-induced hypothalamic-pituitary-adrenal axis activity via multiple actions that vary with time, site of action, and de novo protein synthesis. J. Endocrinol. 208, 311–322 (2011)PubMedPubMedCentral
3.
go back to reference B. Chernow, R. Vigersky, J.T. O’Brian, L.P. Georges, Secondary adrenal insufficiency after intrathecal steroid administration. J. Neurosurg. 56, 567–570 (1982)CrossRefPubMed B. Chernow, R. Vigersky, J.T. O’Brian, L.P. Georges, Secondary adrenal insufficiency after intrathecal steroid administration. J. Neurosurg. 56, 567–570 (1982)CrossRefPubMed
4.
go back to reference C.L. Knight, J.C. Burnell, Systemic side-effects of extradural steroids. Anaesthesia 35, 593–594 (1980)CrossRefPubMed C.L. Knight, J.C. Burnell, Systemic side-effects of extradural steroids. Anaesthesia 35, 593–594 (1980)CrossRefPubMed
5.
go back to reference L.C. Edmonds, M.L. Vance, J.M. Hughes, Morbidity from paraspinal depo corticosteroid injections for analgesia: cushing’s syndrome and adrenal suppression. Anesth. Analg. 72, 820–822 (1991)CrossRefPubMed L.C. Edmonds, M.L. Vance, J.M. Hughes, Morbidity from paraspinal depo corticosteroid injections for analgesia: cushing’s syndrome and adrenal suppression. Anesth. Analg. 72, 820–822 (1991)CrossRefPubMed
6.
go back to reference M.H. Horani, A.B. Silverberg, Secondary Cushing’s syndrome after a single epidural injection of a corticosteroid. Endocr. Pract. 11, 408–410 (2005)CrossRefPubMed M.H. Horani, A.B. Silverberg, Secondary Cushing’s syndrome after a single epidural injection of a corticosteroid. Endocr. Pract. 11, 408–410 (2005)CrossRefPubMed
7.
go back to reference L. Manchikanti, V. Pampati, F.J. Falco, J.A. Hirsch, Assessment of the growth of epidural injections in the medicare population from 2000 to 2011. Pain Physician 16, E349–E364 (2013)PubMed L. Manchikanti, V. Pampati, F.J. Falco, J.A. Hirsch, Assessment of the growth of epidural injections in the medicare population from 2000 to 2011. Pain Physician 16, E349–E364 (2013)PubMed
8.
go back to reference J.M. Burn, L. Langdon, Duration of action of epidural methyl prednisolone. A study in patients with the lumbosciatic syndrome. Am. J. Phys. Med. 53, 29–34 (1974)PubMed J.M. Burn, L. Langdon, Duration of action of epidural methyl prednisolone. A study in patients with the lumbosciatic syndrome. Am. J. Phys. Med. 53, 29–34 (1974)PubMed
9.
go back to reference S. Jacobs, P.T. Pullan, J.M. Potter, G.M. Shenfield, Adrenal suppression following extradural steroids. Anaesthesia 38, 953–956 (1983)CrossRefPubMed S. Jacobs, P.T. Pullan, J.M. Potter, G.M. Shenfield, Adrenal suppression following extradural steroids. Anaesthesia 38, 953–956 (1983)CrossRefPubMed
10.
go back to reference J.F. Maillefert, S. Aho, M.C. Huguenin, C. Chatard, T. Peere, M.F. Marquignon, B. Lucas, C. Tavernier, Systemic effects of epidural dexamethasone injections. Rev. Rhum. Engl. Ed. 62, 429–432 (1995)PubMed J.F. Maillefert, S. Aho, M.C. Huguenin, C. Chatard, T. Peere, M.F. Marquignon, B. Lucas, C. Tavernier, Systemic effects of epidural dexamethasone injections. Rev. Rhum. Engl. Ed. 62, 429–432 (1995)PubMed
11.
go back to reference M. Younes, F. Neffati, M. Touzi, S. Hassen-Zrour, Y. Fendri, I. Bejia, A.A. Ben, N. Bergaoui, M.F. Najjar, Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and non-diabetic patients. Joint Bone Spine 74, 472–476 (2007)CrossRefPubMed M. Younes, F. Neffati, M. Touzi, S. Hassen-Zrour, Y. Fendri, I. Bejia, A.A. Ben, N. Bergaoui, M.F. Najjar, Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and non-diabetic patients. Joint Bone Spine 74, 472–476 (2007)CrossRefPubMed
12.
go back to reference J.Y. Chon, H.S. Moon, Salivary cortisol concentration changes after epidural steroid injection. Pain Physician 15, 461–466 (2012)PubMed J.Y. Chon, H.S. Moon, Salivary cortisol concentration changes after epidural steroid injection. Pain Physician 15, 461–466 (2012)PubMed
13.
go back to reference J. Kay, J.W. Findling, H. Raff, Epidural triamcinolone suppresses the pituitary-adrenal axis in human subjects. Anesth. Analg. 79, 501–505 (1994)CrossRefPubMed J. Kay, J.W. Findling, H. Raff, Epidural triamcinolone suppresses the pituitary-adrenal axis in human subjects. Anesth. Analg. 79, 501–505 (1994)CrossRefPubMed
14.
go back to reference D.W. Gorski, T.L. Rao, S.N. Glisson, M. Chinthagada, A.A. El-Etr, Epidural triamcinolone and adrenal response to hypoglycemic stress in dogs. Anesthesiology 57, 364–366 (1982)CrossRefPubMed D.W. Gorski, T.L. Rao, S.N. Glisson, M. Chinthagada, A.A. El-Etr, Epidural triamcinolone and adrenal response to hypoglycemic stress in dogs. Anesthesiology 57, 364–366 (1982)CrossRefPubMed
15.
go back to reference G. Habib, A. Jabbour, J. Salman, G. Hakim, H. Haddad, The effect of epidural methylprednisolone acetate injection on the hypothalamic-pituitary-adrenal axis. J. Clin. Anesth. 25, 629–633 (2013)CrossRefPubMed G. Habib, A. Jabbour, J. Salman, G. Hakim, H. Haddad, The effect of epidural methylprednisolone acetate injection on the hypothalamic-pituitary-adrenal axis. J. Clin. Anesth. 25, 629–633 (2013)CrossRefPubMed
16.
go back to reference M.C. Lansang, T. Farmer, L. Kennedy, Diagnosing the unrecognized systemic absorption of intra-articular and epidural steroid injections. Endocr. Pract. 15, 225–228 (2009)CrossRefPubMed M.C. Lansang, T. Farmer, L. Kennedy, Diagnosing the unrecognized systemic absorption of intra-articular and epidural steroid injections. Endocr. Pract. 15, 225–228 (2009)CrossRefPubMed
17.
go back to reference A. Iranmanesh, D. Lawson, B. Dunn, J.D. Veldhuis, Glucose ingestion selectively amplifies ACTH and cortisol secretory-burst mass and enhances their joint synchrony in healthy men. J. Clin. Endocrinol. Metab. 96, 2882–2888 (2011)CrossRefPubMedPubMedCentral A. Iranmanesh, D. Lawson, B. Dunn, J.D. Veldhuis, Glucose ingestion selectively amplifies ACTH and cortisol secretory-burst mass and enhances their joint synchrony in healthy men. J. Clin. Endocrinol. Metab. 96, 2882–2888 (2011)CrossRefPubMedPubMedCentral
18.
go back to reference K. Kovacs, S. Wagley, M.T. Quirk, O.M. Ceron, P.A. Silva, R.J. Singh, H.J. Gukasyan, J.G. Arroyo, Pharmacokinetic study of vitreous and serum concentrations of triamcinolone acetonide after posterior sub-tenon’s injection. Am. J. Ophthalmol. 153, 939–948 (2012)CrossRefPubMed K. Kovacs, S. Wagley, M.T. Quirk, O.M. Ceron, P.A. Silva, R.J. Singh, H.J. Gukasyan, J.G. Arroyo, Pharmacokinetic study of vitreous and serum concentrations of triamcinolone acetonide after posterior sub-tenon’s injection. Am. J. Ophthalmol. 153, 939–948 (2012)CrossRefPubMed
19.
go back to reference R.L. Taylor, D. Machacek, R.J. Singh, Validation of a high-throughput liquid chromatography-tandem mass spectrometry method for urinary cortisol and cortisone. Clin. Chem. 48, 1511–1519 (2002)PubMed R.L. Taylor, D. Machacek, R.J. Singh, Validation of a high-throughput liquid chromatography-tandem mass spectrometry method for urinary cortisol and cortisone. Clin. Chem. 48, 1511–1519 (2002)PubMed
20.
go back to reference J.D. Veldhuis, A. Iranmanesh, F. Roelfsema, P. Aoun, P.Y. Takahashi, J.M. Miles, D.M. Keenan, Tripartite control of dynamic ACTH-cortisol dose-responsiveness by age, body mass index and gender in 111 healthy adults. J. Clin. Endocrinol. Metab. 96, 2874–2881 (2011)CrossRefPubMedPubMedCentral J.D. Veldhuis, A. Iranmanesh, F. Roelfsema, P. Aoun, P.Y. Takahashi, J.M. Miles, D.M. Keenan, Tripartite control of dynamic ACTH-cortisol dose-responsiveness by age, body mass index and gender in 111 healthy adults. J. Clin. Endocrinol. Metab. 96, 2874–2881 (2011)CrossRefPubMedPubMedCentral
21.
go back to reference G.M. Bright, Corticosteroid-binding globulin influences kinetic parameters of plasma cortisol transport and clearance. J. Clin. Endocrinol. Metab. 80, 770–775 (1995)PubMed G.M. Bright, Corticosteroid-binding globulin influences kinetic parameters of plasma cortisol transport and clearance. J. Clin. Endocrinol. Metab. 80, 770–775 (1995)PubMed
22.
23.
go back to reference J.H. Zar. Biostatistical analysis. 3rd edn. Prentice Hall, Upper Saddle River, NJ), 1996) J.H. Zar. Biostatistical analysis. 3rd edn. Prentice Hall, Upper Saddle River, NJ), 1996)
24.
go back to reference A.D. Sehgal, D.C. Tweed, W.J. Gardner, M.K. Foote, Laboratory studies after intrathecal corticosteroids: determination of corticosteroids in plasma and cerebrospinal fluid. Arch. Neurol. 9, 64–68 (1963)CrossRefPubMed A.D. Sehgal, D.C. Tweed, W.J. Gardner, M.K. Foote, Laboratory studies after intrathecal corticosteroids: determination of corticosteroids in plasma and cerebrospinal fluid. Arch. Neurol. 9, 64–68 (1963)CrossRefPubMed
Metadata
Title
Hypothalamo-pituitary-adrenal axis after a single epidural triamcinolone injection
Authors
Ali Iranmanesh
Dakshinamurty Gullapalli
Ravinder Singh
Johannes D. Veldhuis
Publication date
01-08-2017
Publisher
Springer US
Published in
Endocrine / Issue 2/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1357-7

Other articles of this Issue 2/2017

Endocrine 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine